Chairman Dilip Shanghvi ne analyst call mein bola ki Sun Pharma M&A mein discipline rakhegi aur organic growth se shareholder value badhane par focus karegi. Unhone bataya ki company US market mein innovative medicines par focus kar rahi hai.
Emerging markets ke liye, company chhoti, "tuck-in" type ki acquisitions soch rahi hai, taaki wahan apni presence badha sake aur operations ko scale up kar sake. Yeh ek measured approach hai, bade acquisitions ke bajaye.
Jab biosimilars ke baare mein poocha gaya, toh chairman ne bataya ki woh manufacturing setup, investment costs, development timelines aur potential returns sab carefully check kar rahe hain. Koi bhi decision soch-samajh kar hi liya jayega.
Company ne yeh bhi ishara diya hai ki agar zaroorat padi toh woh debt bhi raise kar sakti hai, lekin sirf tab jab woh long-term strategic capabilities ko enhance kare aur current growth par focus na bigde.
Overall, Sun Pharma ka kehna hai ki woh apne business ko organically grow karna chahti hai aur investors ke liye consistently value create karna chahti hai. Acquisitions tabhi hongi jab woh company ke long-term strategy ko strong karein.